Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Insight Molecular Diagnostics Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −1 vs. Q2 2024
- Shares held
- 7.17M
- +96.6K (+1.4%) vs. Q2 2024
- Total value
- $20.4M
- −$431.2K (−2.1%) vs. Q2 2024
- New holders
- 3
- 4 more added
- Sold out
- 4
- 4 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMDX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 40 | $108.9M |
| Q1 2026 | 41 | $62.1M |
| Q4 2025 | 35 | $124.9M |
| Q3 2025 | 27 | $54.1M |
| Q2 2025 | 30 | $48.9M |
| Q1 2025 | 30 | $49.2M |
| Q4 2024 | 27 | $20.0M |
| Q3 2024 | 21 | $20.4M |
| Q2 2024 | 23 | $21.1M |
| Q1 2024 | 25 | $12.8M |
| Q4 2023 | 26 | $11.1M |
| Q3 2023 | 30 | $14.3M |
| Q2 2023 | 47 | $21.1M |
| Q1 2023 | 52 | $19.7M |
| Q4 2022 | 59 | $19.5M |
| Q3 2022 | 65 | $48.3M |
| Q2 2022 | 76 | $61.8M |
| Q1 2022 | 86 | $81.1M |
| Q4 2021 | 89 | $120.1M |
| Q3 2021 | 95 | $201.9M |
| Q2 2021 | 91 | $324.6M |
| Q1 2021 | 87 | $283.0M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Insight Molecular Diagnostics Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Broadwood Capital Inc | 4,929,066 | $14.0M | 1.08% | 00.0% | Unchanged |
| AWM Investment Company, Inc. | 1,097,175 | $3.13M | 0.38% | 00.0% | Unchanged |
| Pura Vida Investments, LLC | 495,345 | $1.41M | 2.32% | 00.0% | Unchanged |
| Vanguard Group Inc | 245,388 | $699.4K | 0.00% | +899+0.4% | Added |
| Geode Capital Management, LLC | 103,980 | $296.4K | 0.00% | +11,289+12.2% | Added |
| BlackRock, Inc. | 79,833 | $227.5K | 0.00% | +79,833 | New |
| Morgan Stanley | 72,289 | $206.0K | 0.00% | −6,407−8.1% | Reduced |
| Defender Capital, LLC. | 59,353 | $169.2K | 0.06% | +4,133+7.5% | Added |
| FNY Investment Advisers, LLC | 42,896 | $122.0K | 0.06% | +19,242+81.3% | Added |
| State Street Corp | 19,554 | $55.7K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 17,346 | $49.4K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,446 | $4.12K | 0.00% | −1,623−52.9% | Reduced |
| Advisor Group Holdings, Inc. | 1,080 | $3.08K | 0.00% | −47−4.2% | Reduced |
| UBS Group AG | 835 | $2.38K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 412 | $1.17K | 0.00% | −4−1.0% | Reduced |
| Bryn Mawr Trust Co | 250 | $713 | 0.00% | +250 | New |
| JPMorgan Chase & Co | 154 | $439 | 0.00% | 00.0% | Unchanged |
| Piscataqua Savings Bank | 25 | $71 | 0.00% | 00.0% | Unchanged |
| Coppell Advisory Solutions LLC | 10 | $29 | 0.00% | 00.0% | Unchanged |
| Albion Financial Group | 7 | $20 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 1 | $3 | 0.00% | +1 | New |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −10,418−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Riggs Asset Managment Co. Inc. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |